Fibrinolysis shutdown is associated with a fivefold increase in mortality in trauma patients lacking hypersensitivity to tissue plasminogen activator

Journal of Trauma and Acute Care Surgery

Volumn 83, Issue 6, 2017, Pages 1014-1022

  Moore, Hunter B ^a   Moore, Ernest E ^a,b   Huebner, Benjamin R ^a   Dzieciatkowska, Monika ^a   Stettler, Gregory R ^a   Nunns, Geoffrey R ^a   Lawson, Peter J ^a   Ghasabyan, Arsen ^b   Chandler, James ^b   Banerjee, Anirban ^a   Silliman, Christopher ^a   Sauaia, Angela ^a   Hansen, Kirk C ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

Fibrinolysis; fibrinolysis shutdown; platelet dysfunction; tissue plasminogen activator; trauma induced coagulopathy

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME RELEASE; FEMALE; FIBRINOLYSIS; HUMAN; INJURY; INJURY SCALE; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; PRIORITY JOURNAL; PROTEOMICS; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; BLOOD; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; MIDDLE AGED; MORTALITY; PHENOTYPE; PHYSIOLOGY; PROGNOSIS; PROSPECTIVE STUDY;

ADULT; BIOMARKERS; BLOOD COAGULATION DISORDERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; FOLLOW-UP STUDIES; HUMANS; INJURY SEVERITY SCORE; MALE; MIDDLE AGED; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; PROSPECTIVE STUDIES; PROTEOMICS; THROMBELASTOGRAPHY; WOUNDS AND INJURIES;

EID: 85037042159     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0000000000001718     Document Type: Article

References (34)

1. Stafford JL. The Fibrinolytic Mechanism in Haemostasis: A Review. J Clin Pathol. 1964;17:520-530.
2. Moore HB, Moore EE, Gonzalez E, Chapman MP, Chin TL, Silliman CC, Banerjee A, Sauaia A. Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy. J Trauma Acute Care Surg. 2014;77(6):811-817; discussion 7.
3. Moore HB, Moore EE, Liras IN, Gonzalez E, Harvin JA, Holcomb JB, Sauaia A, Cotton BA. Acute fibrinolysis shutdown after injury occurs frequently and increases mortality: a multicenter evaluation of 2, 540 severely injured patients. J Am Coll Surg. 2016;222(4):347-355.
4. Leeper CM, Neal MD, McKenna C, Sperry J, Gaines BA. Abnormalities in fibrinolysis at the time of admission are associated with DVT, mortality and disability in a pediatric trauma population. J Trauma Acute Care Surg. 2016.
5. Hardaway RM, Johnson DG. Influence of fibrinolysin on shock. JAMA. 1963;183:597-599.
6. Killewich LA, Macko RF, Gardner AW, Cox K, Lilly MP, Flinn WR. Defective fibrinolysis occurs after infrainguinal reconstruction. J Vasc Surg. 1997;25(5):858-864; discussion 65.
7. Páramo JA, Rifón J, Llorens R, Casares J, Paloma MJ, Rocha E. Intra- and postoperative fibrinolysis in patients undergoing cardiopulmonary bypass surgery. Haemostasis. 1991;21(1):58-64.
8. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol. 1988;70(3):327-333.
9. Moore HB, Moore EE, Chapman MP, Gonzalez E, Slaughter AL, Morton AP, D'Alessandro A, Hansen KC, Sauaia A, Banerjee A, et al. Viscoelastic measurements of platelet function, not fibrinogen function, predicts sensitivity to tissue-type plasminogen activator in trauma patients. J Thromb Haemost. 2015;13(10):1878-1887.
10. Chapman MP, Moore EE, Moore HB, Gonzalez E, Gamboni F, Chandler JG, Mitra S, Ghasabyan A, Chin TL, Sauaia A, et al. Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients. J Trauma Acute Care Surg. 2016;80(1): 16-23; discussion -5.
11. Cardenas JC, Matijevic N, Baer LA, Holcomb JB, Cotton BA, Wade CE. Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients. Shock. 2014;41(6): 514-521.
12. Kalady MF, Lawson JH, Sorrell RD, Platt JL. Decreased fibrinolytic activity in porcine-to-primate cardiac xenotransplantation. Mol Med. 1998;4(9):629-637.
13. Neal MD, Moore HB, Moore EE, Freeman K, Cohen MJ, Sperry JL, Zuckerbraun BS, Park MS. TACTIC Investigators. Clinical assessment of trauma-induced coagulopathy and its contribution to postinjury mortality: A TACTIC proposal. J Trauma Acute Care Surg. 2015;79(3): 490-492.
14. Moore HB, Moore EE, Gonzalez E, Wiener G, Chapman MP, Dzieciatkowska M, Sauaia A, Banerjee A, Hansen KC, Silliman C. Plasma is the physiologic buffer of tissue plasminogen activator-mediated fibrinolysis: rationale for plasma-first resuscitation after life-threatening hemorrhage. J Am Coll Surg. 2015.
15. Moore HB, Moore EE, Gonzalez E, Hansen KC, Dzieciatkowska M, Chapman MP, Sauaia A, West B, Banerjee A, Silliman CC.Hemolysis exacerbates hyperfibrinolysis, whereas platelolysis shuts down fibrinolysis: evolving concepts of the spectrum of fibrinolysis in response to severe injury. Shock. 2015;43(1):39-46.
16. Wohlauer MV, Moore EE, Thomas S, Sauaia A, Evans E, Harr J, Silliman CC, Ploplis V, Castellino FJ, Walsh M. Early platelet dysfunction: an unrecognized role in the acute coagulopathy of trauma. J Am Coll Surg. 2012;214(5):739-746.
17. Bartels AN, Johnson C, Lewis J, Clevenger JW, Barnes SL, Hammer RD, Ahmad S. Platelet adenosine diphosphate inhibition in trauma patients by thromboelastography correlates with paradoxical increase in platelet dense granule content by flow cytometry. Surgery. 2016;160(4):954-959.
18. Pareti FI, Capitanio A, Mannucci L, Ponticelli C, Mannucci PM. Acquired dysfunction due to the circulation of "exhausted" platelets. Am J Med. 1980;69(2):235-240.
19. Moore HB, Moore EE, Gonzalez E, Wiener G, Chapman MP, Dzieciatkowska M, Sauaia A, Banerjee A, Hansen KC, Silliman C. Plasma is the physiologic buffer of tissue plasminogen activator-mediated fibrinolysis: rationale for plasma-first resuscitation after life-threatening hemorrhage. J Am Coll Surg. 2015;220(5):872-879.
20. Booth NA, Walker E, Maughan R, Bennett B. Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with C1-inhibitor and PAI-1. Blood. 1987;69(6):1600-1604.
21. Bouma BN, Marx PF, Mosnier LO, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res. 2001;101(5):329-354.
22. Mutch NJ, Koikkalainen JS, Fraser SR, Duthie KM, Griffin M, Mitchell J, Watson HG, Booth NA. Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis. J Thromb Haemost. 2010;8(9):2017-2024.
23. Booth NA. Fibrinolysis and thrombosis. Baillieres Best Pract Res Clin Haematol. 1999;12(3):423-433.
24. Raza I, Davenport R, Rourke C, Platton S, Manson J, Spoors C, Khan S, De'Ath HD, Allard S, Hart DP, et al. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost. 2013;11(2): 307-314.
25. Huber D, Cramer EM, Kaufmann JE, Meda P, Masse JM, Kruithof EK, Vischer UM. Tissue-type plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo. Blood. 2002;99(10):3637-3645.
26. Bhandary YP, Shetty SK, Marudamuthu AS, Gyetko MR, Idell S, Gharaee-Kermani M, Shetty RS, Starcher BC, Shetty S. Regulation of alveolar epithelial cell apoptosis and pulmonary fibrosis by coordinate expression of components of the fibrinolytic system. Am J Physiol Lung Cell Mol Physiol. 2012;302(5):L463-L473.
27. Moore HB, Gonzalez E, Huebner BJ, Sheppard F, Banerjee A, Sauaia A, Silliman CC. Reperfusion shutdown: delayed onset of fibrinolysis resistance after resuscitation from hemorrhagic shock is associated with increased hcirculating levels of plasminogen activator inhibitor-1 and postinjury complications. Blood. 2016;128:206.
28. Meizoso JP, Karcutskie CA, Ray JJ, Namias N, Schulman CI, Proctor KG. Persistent fibrinolysis shutdown associated with increased mortality in severely injured trauma patients. J Am Coll Surg. 2017;224(4):575-582.
29. Harvin JA, Peirce CA, Mims MM, Hudson JA, Podbielski JM, Wade CE, Holcomb JB, Cotton BA. The impact of tranexamic acid on mortality in injured patientswith hyperfibrinolysis. J Trauma Acute Care Surg. 2015;78(5):905-911.
30. Davenport RA, Guerreiro M, Frith D, Rourke C, Platton S, Cohen M, Pearse R, Thiemermann C, Brohi K. Activated protein C drives the hyperfibrinolysis of acute traumatic coagulopathy. Anesthesiology. 2017;126(1):115-127.
31. Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, del Junco DJ, Brasel KJ, Bulger EM, Callcut RA, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471-482.
32. Gonzalez E, Moore EE, Moore HB, Chapman MP, Chin TL, Ghasabyan A, Wohlauer MV, Barnett CC, Bensard DD, Biffl WL, et al. Goal-directed hemostatic resuscitation of trauma-induced coagulopathy: a pragmatic randomized clinical trial comparing a viscoelastic assay to conventional coagulation assays. Ann Surg. 2016;263(6):1051-1059.
33. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, de Gans K, Koopman MM, Brand A, Majoie CB, Beenen LF, Marquering HA, Vermeulen M, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet. 2016;387(10038):2605-2613.
34. Brohi K, Cohen MJ, Davenport RA. Acute coagulopathy of trauma: mechanism, identification and effect. Curr Opin Crit Care. 2007;13(6):680-685.